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Abstract
Background: The role of Chlamydophila pneumoniae (CP) in the progression of atheroscle-
rosis is controversial. Also no sufficient angiographic study is available about the impact of CP
infection on severity and intensity of coronary atherosclerosis. We investigated the relation
between CP IgG antibody titers and severity and intensity of coronary atherosclerosis
Methods: The study population consisted of 516 consecutive patients who underwent
a coronary angiography. The group included 353 patients who had coronary artery disease;
a control group included 163 subjects with angiographically proven normal coronary arteries.
Chlamydophila pneumoniae IgG antibody titers were measured by an enzyme immunoassay
method in all patients. Gensini scores and extent scores were used to evaluate the angiographic
extent and severity of atherosclerosis.
Results: The mean value of IgG antibody titer was 44.3 ± 28.8 IU/mL in the patients and
39.8±27.4 IU/mL in the control group (p = 0.14). There was no statistically significant
correlation between the Gensini scores, extent scores and CP IgG titers (Gensini score: r = +0.103,
p = 0.07, extent score: r = +0.110, p = 0.31). When we grouped the patients as high (> 50 IU/mL)
and low (< 50 IU/mL) IgG antibody titers, the number of diseased coronary arteries was
higher in patients with high IgG antibody titers (respectively: 2.6 ± 1.1 vs. 2.2 ± 0.8, p = 0.01).
While the Gensini score was significantly higher in patients with high IgG antibody titers
(7.5 ± 4.0 vs. 6.17 ± 4.0, p = 0.01), the extent score did not change with IgG titers (29.8 ± 15.9
vs. 25.8 ± 15.4, p = 0.08).
Conclusions: In our study, we investigated the relation between CP infection and coronary
atherosclerosis and found that CP IgG antibody titers are associated with the severity of
coronary stenosis at higher antibody levels. However, there is no association between CP
antibody titers and clinical presentation of coronary artery disease. We suggest that CP has
limited effect on coronary atherosclerosis. (Cardiol J 2008; 15: 245–251)
Key words: Chlamydophila pneumoniae, atherosclerosis, gensini and extent score
246
Cardiology Journal 2008, Vol. 15, No. 3
www.cardiologyjournal.org
Introduction
Atherosclerosis is a multifactorial process and
it is considered to be an inflammatory disease [1, 2].
The inflammation plays a central role in both pa-
thogenesis of atherosclerotic vascular disease and
its atherothrombotic complications [3]. It has been
postulated that chronic infection with various patho-
gens may promote arterial inflammation, thereby con-
tributing to the initiation or progression of athero-
sclerosis. The potential role of infectious agents in the
pathogenesis and progression of atherosclerosis has
been studied in several studies recently [4–6].
Chlamydophila pneumoniae (CP), an important
cause of atypical pneumonia is an obligate intracel-
lular human pathogen [7]. Saikku et al. [8] showed
that patients with coronary artery disease (CAD)
had elevated antibody titers against CP. This has
been detected in human atherosclerotic plaques [9].
Furthermore, recent clinical studies have investi-
gated the possibility of treating CAD with anti-chla-
mydial antibiotic therapy [10–13].
Although present studies may differ, the role
of CP on atherosclerosis is still a matter of contro-
versy. Also no sufficient angiographic study is ava-
ilable about the impact of CP infection on severity
and intensity of coronary atherosclerosis. Therefore
in our study we aim to detect whether a relation
exists between CP antibody titers and angiographic
severity and intensity of coronary atherosclerosis and
clinical presentation of CAD. In addition, we evaluated
the highly sensitive C-reactive protein (CRP) levels
and their relation both with CAD and CP infection.
Methods
Study population
The study population consisted of 516 patients
(mean age: 56.8 ± 10.4 years, 326 M) in whom CAD
was suspected and a coronary angiography was per-
formed in the cardiology department of Erciyes
University. The study was approved by the local
ethics committee. All patients were informed and
informed consent was obtained.
The patient group included 353 patients with
angiographically proven CAD, which contained
3 different subgroups: 163 patients with myocardial
infarction (MI), 106 patients with unstable angina
pectoris (USAP) and 84 patients with stable angina
pectoris (SAP). The control group included
163 subjects with angiographically proven normal
coronary arteries.
The patients who had acute MI were defined
by a positive troponin test and elevated cardiac
markers with typical chest pain or electrocardiogra-
phic changes consistent with MI [6, 14]. Unstable
angina was diagnosed if the patient had a positive
or negative troponin test with normal cardiac mar-
kers or any one of the following criteria: new onset
angina (< 2 months) of at least class III according
to the Canadian Cardiovascular Society, prolonged
(> 20 min) angina at rest, recent (< 2 months)
worsening of angina pectoris, or angina that occur-
red within 2 weeks of an acute MI [15]. Stable an-
gina pectoris was defined by its clinical presenta-
tion of discomfort in the chest, typically aggrava-
ted by exertion or emotional stress, and relieved
by nitroglycerin administration or rest. Normal co-
ronary artery was defined as a completely clean co-
ronary artery without any obstructive or non-ob-
structive lesions.
The study was approved by the local bioethi-
cal committe and all patients gave their informed
consent.
Exclusion criteria
Patients with active infective disease, known
connective tissue diseases, pulmonary, renal, he-
patic and hematological disorders were excluded
from the study.
Blood analysis
Peripheral blood samples were taken from an
antecubital vein after admission to the hospital.
Serum fasting blood glucose, total cholesterol, tri-
glyceride, and HDL-cholesterol levels were deter-
mined by enzymatic methods after 12 hours fasting.
Lipid parameters were measured by the advice of
Konelab 60I (Thermo Clinical Lab Systems) with
original Thermo kits. LDL-cholesterol was calcula-
ted with Friedewald formula [16]. CRP was measu-
red by Behring nephelometry system kits. A level
above 6 mg/dl was accepted as a positive result.
Serological analysis
Blood samples were taken during a coronary
angiography. Determination of specific IgG antibo-
dies against CP were performed by ELISA enzyme
immunoassay kit (CPG/0604) DIO.PRO as previo-
usly described [17–19]. The remaining blood was
centrifuged for 10 to 30 minutes and separated. Pla-
sma and serum specimens were frozen and stored
at –70°C until analysis. In each instance, kits were
stored at 4°C and allowed to stand at room tempe-
rature for one hour before use. The serum samples
for analysis were diluted 1:101 with a sample buf-
fer. In the first reaction step, diluted patient sam-
ples were incubated with the wells. To detect the
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bound antibodies, a second incubation was carried
out using enzyme-labelled anti-human IgG, which
was capable of promoting a colour reaction. After
washing and drying, photometric measurements of
the colour intensity were made at a wave length of
450 nm and a reference wavelength of > 620 nm
within 30 min of adding the stop solution. Results
were expressed as enzyme immuno units (IU) cal-
culated relative to a calibrator specimen. Seroposi-
tivity was defined as an IgG titer higher than cut
off (5 IU/mL).
To evaluate the effect of low and high CP IgG
antibody titers on coronary atherosclerosis, we clas-
sified patients into two subgroups as with low
(< 50 IU/mL) and high (50 IU/mL) antibody titers.
Coronary angiography findings were compared be-
tween these two groups.
Coronary angiography
Selective coronary angiography was performed
with 6 F or 7 F Judkins catheters. All images were
acquired on a Philips Integris H 5000 at 25 frames/
/second. The numbers of major vessels with any
luminal stenosis (lumen diameter reduction) was
scored from 1 to 3 vessel disease (right, left ante-
rior descending, and circumflex arteries). Left main
stenosis ≥ 50% was scored as two vessel disease if
there was no lesion ≥ 50% in the other vessels. The
results of the angiography were evaluated by two
cardiologists who were blinded to the results for CP
IgG levels.
Gensini score
We used the Gensini score to evaluate the seve-
rity of atherosclerosis. The modified Gensini score has
been described and validated previously [20, 21]. The
most severe stenosis in each of eight coronary seg-
ments was graded from 1 to 4 (1 to 49% lumen dia-
meter reduction: 1 point, 50 to 74% stenosis: 2,
75 to 99% stenosis: 3, 100% occlusion: 4) to give
a total score of between 0 and 32. This score there-
fore gives an index of the severity of coronary athe-
rosclerosis.
Extent score
We used the extent score to evaluate the in-
tensity of atherosclerosis. This score was develo-
ped by Sullivan et al. [22] to indicate the percenta-
ge (0% to 100%) of the coronary surface involved
by atheroma. The proportion of each vessel invo-
lved by atheroma, as identified by lumen irregula-
rity, was multiplied by a factor for each vessel: left
main, 5; left anterior descending, 20; main diagonal
branch, 10; first septal perforator, 5; left circumflex,
obtuse marginal, and posterolateral vessels, 10;
right coronary, 20; and main posterior descending
branch, 10. When the major lateral wall branch was
a large obtuse marginal or intermediate vessel, the
factor used was 20, with factor of 10 for the left cir-
cumflex. Occluded vessels which were filled with
contrast medium by collateral flow were evaluated
according to the visible irregularities of the vessel
wall. If no collateral flow existed, the mean value of
all the other vessel segments in this angiogram
were transferred to this occluded vessel segment.
Therefore this score gives a measure for extent of
coronary atherosclerosis
Statistical analysis
Data are expressed as mean ± SD, percenta-
ge or median (Interquartile (25th to 75th) ranges)
(IQR). Kolmogorov-Smirnov tests were used to
assess the distributions of numeric parameters.
Spearman correlation analyses were performed to
test for correlation analyses. Comparisons betwe-
en the groups were carried out using Student’s
t test, Mann-Whitney U test, ANOVA, and the c2
test. All probability values reported are two-tailed,
with values of p < 0.05 considered statistically si-
gnificant. The SPSS 11.0 software was used for sta-
tistical analysis.
Results
Baseline characteristics are shown in Table 1.
History of diabetes, hypertension, smoking, LDL le-
vel and age were similar in patient and control groups.
The mean IgG antibody titer was 44.3 ±
± 28.8 IU/mL in the patient group and 39.8 ±
± 27.4 IU/mL in the control group (p = 0.14) and
the CP seropositivity ratio was similar between the
two groups (patient group: 92.9% vs. control gro-
up: 91.7%, p > 0.05).
In the patient group, the number of diseased
coronary arteries was 2.4 ± 0.9. The mean Gensini
score was 6.7 ± 4.0 and the extent score was 27.2 ±
± 15.3. There was no statistically significant corre-
lation between both the Gensini and extent score and
CP IgG titers (with Gensini score: r = +0.103,
p = 0.07, with extent score: r = +0.110, p = 0.31).
When we grouped the patients as high (> 50 IU/
/mL) or low (< 50 IU/mL) IgG antibody titers,
IgG titers in 58% of all patients had above 50 IU/mL.
The number of diseased coronary arteries was
higher in patients with high IgG levels than patients
with low IgG levels (2.6 ± 1.1 vs. 2.2 ± 0.8, p = 0.01,
respectively). While Gensini score was significan-
tly higher in patients with high IgG titers, extent
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score did not change with IgG levels (Fig. 1, 2). In
the subgroup analysis of patients with CAD, sero-
positivity ratios and IgG levels were similar betwe-
en the three subgroups Table 2.
The CRP level was significantly higher in the
patient group than the control group [median: 9.83
(IQR: 3–30) mg/dL vs. 3.3 (IQR: 3–10) mg/dL, re-
spectively, p < 0.001]. The CRP level was positi-
vely correlated with both extent and Gensini score
(r = +0.324, p < 0.001; r = +0.307, p < 0.001).
However CRP levels in patients who had IgG
level > 50 was similar to patients with low IgG le-
vels [median: 15.2 (IQR: 4–46) vs. 11.0 (IQR: 3–30),
respectively, p = 0.14].
The CRP levels were significantly higher in the
MI group than the other two groups [median, MI:
20.9 (IQR: 7–59), USAP: 4.5 (IQR: 3–17), SAP: 3.6
(IQR: 3–10), p < 0.001] No significant correlation
was observed between the CRP levels and the CP
IgG titers (r =–0.031 p = 0.4).
Table 2. Comparison of IgG level and seropositivity in the subgroups.
Myocardial infarction Unstable angina Stable angina P
(n = 163) pectoris  (n = 106)  pectoris  (n = 84)
Rate of seropositivity (%) 95.5 91.1 92.9 0.7
IgG level [IU/mL] (X ± SD) 45.1 ± 28.6 45.2 ± 30.3 38.9 ± 28.6 0.4
Data are presented as the mean value ± SD or percentage of seropositivity
Figure 1. Gensini score in patients with a Chlamydophila
pneumoniae (CP) IgG level above and below 50 IU/mL.
Data are presented as the mean value ± SD; NS:
p < 0.05 accepted statistically significant.
Figure 2. Extent score in patients with a Chlamydophila
pneumoniae (CP) IgG level above and below 50 IU/mL.
Data are presented as the mean value ± SD; NS:
p < 0.05 accepted statistically significant.
Table 1. Patient characteristics.
Patient group (n = 353) Control group (n = 163) p
Age (years) 56.4±10.1 57.2±7.7 NS
Male (%) 62 47 < 0.05
Diabetes mellitus (%) 16.5 11.9 NS
Hypertension (%) 33.5 35.1 NS
Current smoking (%) 37 31 NS
Total cholesterol [mg /dL] 187±39 184±44 NS
LDL-cholesterol [mg /dL] 143±36 144±35 NS
HDL-cholesterol [mg /dL] 48±12. 50±21 NS
Triglycerides [mg/dL] 151.±105 157±104 NS
Data are presented as the mean value ± SD or percentage of patients; p < 0.05 accepted statistically significant; NS — non significant
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Discussion
The association between CP infection and athe-
rosclerosis is still not known. Despite a possible
association that was shown in some studies [6, 8,
9, 23], there is limited data about the relation be-
tween CP infection and angiographic findings of co-
ronary atherosclerosis. In some previous studies
which investigated the association between CP in-
fection and severity of atherosclerosis, atheroscle-
rosis severity was evaluated by different methods in
different patient groups. In one study, Imai et al. [24]
evaluated the severity of atherosclerosis by the
Gensini score but there were only patients with
stable angina pectoris in this study. Wang et al.  [25]
investigated severity and extent of CAD by the
number of major epicardial coronary arteries invo-
lved and by the Duke risk score. Although Yavuz
et al. [26] investigated the relation between athe-
rosclerosis and seropositivity in patients with su-
spected CAD, authors used only Gensini score for
the severity of atherosclerosis. Moreover the rela-
tion between CP infection and the clinical presen-
tation of coronary artery disease was not investi-
gated in these studies. In our study, we evaluated
atherosclerosis by diseased vessel number, Gensini
and extent score. Therefore we aimed to determine
whether CP infection increases the degree of athero-
sclerosis and affects the stages of atherosclerosis. We
also investigated the relation between CP infection
and CAD subgroup. According to our data, CP infec-
tion seems to be related only to angiographic corona-
ry stenosis. Severity of atherosclerosis was higher in
patients with high CP antibody titers. However, we
did not find any relation between CP IgG levels and
extent of atherosclerosis. Our results are concordant
with a recently published study by Videm  et al. [27].
The authors show that IgG against the CP protein
antigen is more frequent in patients with significant
coronary artery stenosis.
There are different opinions about which sta-
ge of atherosclerosis CP affects. Despite some stu-
dies suggesting that CP may affect early stages of
atherosclerosis [28] other results do not support
that idea [29, 30]. Gensini and extent scores which
we used in our study may show different stages of
atherosclerosis. While extent scores show the an-
giographic amount of plaque independent of steno-
sis severity, the Gensini score indicates the degree
of stenotic coronary lesions which occur predomi-
nantly in the late phase of atherosclerosis. It is an
acceptable result that the late phase of atheroscle-
rosis may be evaluated by the Gensini score.
According to our results, CP infection correlates only
with stenosis severity not with the extent of athe-
rosclerosis. These results show that CP infection
may be associated with progression of the athero-
sclerotic process and this relation may become evi-
dent at high antibody levels. Ericson et al. [30], in
a postmortem study, found that direct immunoflu-
orescence for CP was positive in 86% of cases with
severe atherosclerosis but in only 6% of cases with
mild atherosclerosis. Although seropositivity for CP
is rather high (70–80%) in the population, the fact
that CP reactivity is very rare in mild lesions and
very high in severe lesions may be histopathologic
evidence of our opinion.
In the second part of the study, we demonstra-
ted that although CP antibody titer was associated
only with severity of stenosis, CRP level was asso-
ciated with both severity and intensity of atherosc-
lerosis. However we did not find any relation be-
tween CP infection and CRP levels. In a report, An-
derson et al. [31] showed borderline significant
association between elevated CRP and combined
seropositivity for Helicobacter pylori and CP, but
not for CP alone. Further, it was found there was
no significant relation of CP seropositivity with pla-
sma level of CRP in the Physicians Health Study
[32]. In our study, obtaining no relation between
CRP level and CP antibody titer or correlation be-
tween CRP levels and atherosclerosis make us con-
sider that CRP is related to the atherosclerosis
independent of CP infection and that chronic CP
infection does not lead to the increase in systemic
inflammatory activity such as CRP.
Another controversial subject is the relation
between CP infection and the presentation of ACS.
Our other purpose was to evaluate the role of CP
infection in different clinical types of coronary ar-
tery disease, comparing serological data of patients
between stable angina, unstable angina, and acute
MI. Although previous studies failed to demonstrate
an association between antibodies to CP and ACS
[33–35], the association between CP infection and
ACS was demonstrated in some studies. In a recent
publication, Liu et al. [36] showed that the number
of CP positive cells in coronary plaques was gre-
ater in ACS patients (21 patients) than in non-ACS
patients (17 patients). However several clinical stu-
dies have investigated the possibility of treating
coronary patients with antichlamydial antibiotic the-
rapy [10–13]. In a meta analysis of the studies which
investigated effects of anticlamydial therapy on the
outcome of patients, there was no significant bene-
fit on any of these end points such as total mortality,
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MI, and ACS [37]. Despite the possible relation
between CP infection and ACS, we found that the
titers of antichlamydial antibodies and seropositi-
vity of CP are not different in the subgroups of CAD.
These findings indicate that although CP infection
may affect progression of atherosclerosis, it does
not play a significant role in inducing plaque activa-
tion or presentation of CAD. Both obtaining no re-
duction in cardiac event rate with antibiotic thera-
py for CP in large randomized controlled trials and
serologic studies support our data.
Limitations of the study
The number of patients seronegative for CP
infection was very low in our study. Therefore we
could not evaluate severity and intensity of athero-
sclerosis between seropositive and seronegative
patients. IgM antibody seropositivity for CP infec-
tion is very rare. We think that it would be difficult
to find enough CP IgM positive patients to compa-
re the groups therefore we only analyze IgG anti-
body titers. Although we evaluated severity and
intensity of atherosclerosis, we did not investigate
the relation between morphologic properties of
atherosclerosis and CP infection. While we suggest
that CP affects only the late phase of atherosclero-
sis, we evaluated atherosclerosis only angiographi-
cally. We think that for definitive evidence about
which stage of atherosclerosis is affected by CP
infection, intravascular ultrasound studies need to
be performed.
Conclusions
In our study, we investigated the association
between CP infection and coronary atherosclerosis
and found that CP IgG antibody titers are associa-
ted with the severity of coronary stenosis at higher
antibody levels. There is no association between CP
antibody titers and the clinical presentation of CAD.
We suggest that CP has limited effects on the pro-
gression of coronary atherosclerosis and these ne-
gative effects emerge only at high antibody levels.
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